Using CAR T cell therapy to treat severe allergic diseases.
Chimeric antigen receptor (CAR) T cell therapy for severe allergic diseases.
['FUNDING_OTHER'] · CELLERGY PHARMA · NIH-10822618
This study is exploring a new way to help people with severe allergies by using a special treatment called CAR T cell therapy, which could provide lasting relief from allergy symptoms with just one treatment, instead of relying on medications that can have unwanted side effects.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CELLERGY PHARMA (nih funded) |
| Locations | 1 site (Wilmington, UNITED STATES) |
| Trial ID | NIH-10822618 on ClinicalTrials.gov |
What this research studies
This research investigates the use of chimeric antigen receptor (CAR) T cell therapy as a potential treatment for severe allergic diseases, which affect millions of Americans. The approach involves modifying T cells to target and eliminate the underlying causes of allergic reactions, aiming for long-term symptom relief with a single treatment. By leveraging the success of CAR T cell therapy in cancer treatment, this study seeks to provide a novel solution for patients who currently rely on corticosteroids and other long-term therapies that have significant side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who suffer from severe allergic conditions such as asthma, food allergies, or chronic urticaria.
Not a fit: Patients with mild allergic conditions or those who do not meet the age requirement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a long-lasting treatment option for patients suffering from severe allergic diseases, potentially reducing their reliance on corticosteroids and improving their quality of life.
How similar studies have performed: While CAR T cell therapy has shown remarkable success in treating certain cancers, its application in severe allergic diseases is novel and has not been extensively tested.
Where this research is happening
Wilmington, UNITED STATES
- CELLERGY PHARMA — Wilmington, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MA, ZHENGYU — CELLERGY PHARMA
- Study coordinator: MA, ZHENGYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.